Malignant Digestive System Neoplasm

cancer family

Identifier: CI-CAN-00000229
Entity page: /cancer/malignant-digestive-system-neoplasm ↗
Edges: 14,652

Neighbours: 15 genes21 drugs10 trials
Drawn: 46 of 46 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Digestive System Neoplasm approved for …APPROVED_FORderived15 of 67show all (up to 200)
← approved for	Fluorouracilsmall molecule FDA (US) · approved · 2026-02-20 · Pancreatic Adenocarcinoma	—	approved	Pancreatic Adenocarcinoma	1	Regulatory	openfda	graph →
← approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

FGFR2 Fusion Infigratinib0 active / 6 trials
Curatedlevel Asensitivity· support 3civicObservedFGFR2 altered in 3% (41 / 1,370 cases)no approval record in this cancercontext: Cholangiocarcinoma
FGFR2 Fusion Infigratinib0 active / 6 trials
Curatedlevel Asensitivity· support 3civicObservedFGFR2 altered in 3% (41 / 1,370 cases)no approval record in this cancercontext: Cholangiocarcinoma
IDH1 R132 IvosidenibFDA US 2018-07-207 active / 10 trials
Curatedlevel Asensitivity· support 1civicObservedIDH1 altered in 10% (141 / 1,370 cases, largest of 2 cohorts)Regulatoryapproved for Cholangiocarcinomacontext: Cholangiocarcinoma
FGFR2 Fusion PemigatinibFDA US 2020-04-175 active / 14 trials
Curatedlevel Asensitivity· support 1civicObservedFGFR2 altered in 3% (41 / 1,370 cases)Regulatoryapproved for Cholangiocarcinoma (2 approval records)context: Cholangiolocellular Small Duct Intrahepatic Cholangiocarcinoma
FGFR2 Fusion PemigatinibFDA US 2020-04-175 active / 14 trials
Curatedlevel Asensitivity· support 1civicObservedFGFR2 altered in 3% (41 / 1,370 cases)Regulatoryapproved for Cholangiocarcinoma (2 approval records)context: Cholangiolocellular Small Duct Intrahepatic Cholangiocarcinoma
BRCA2 Loss-of-function OlaparibFDA US 2017-08-1719 active / 40 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA2 altered in 2.1% (29 / 1,370 cases, largest of 2 cohorts)Regulatoryapproved for Pancreatic Adenocarcinomacontext: Pancreatic Adenocarcinoma
BRCA1 Loss-of-function OlaparibFDA US 2017-08-1719 active / 40 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BRCA1 in this cancerRegulatoryapproved for Pancreatic Adenocarcinomacontext: Pancreatic Adenocarcinoma
NRG1 Fusion Zenocutuzumab-zbco0 active / 1 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for NRG1 in this cancerno approval record in this cancercontext: Pancreatic Adenocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Malignant Digestive System Neoplasm altered in cohorts of …ALTERED_INderived15 of 619show all (up to 200)
← altered in cohorts of	HTR6 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	KLHDC7A 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MRTO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TAS1R2 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TMCO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AADACL3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AADACL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTL8 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AHDC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AKR7A3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ALDH4A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ALPL 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ARHGEF10L 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ASAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ATP13A2 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →

Malignant Digestive System Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 334show all (up to 200)
→ investigated in trials for	Gemcitabinesmall molecule 690 trials (149 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	690	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 489 trials (141 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	489	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 485 trials (124 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	485	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 406 trials (103 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	406	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 390 trials (92 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	390	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 282 trials (110 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	282	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 270 trials (70 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	270	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 269 trials (99 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	269	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 262 trials (94 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	262	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 253 trials (70 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	253	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 247 trials (76 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	247	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 217 trials (79 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	217	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenibsmall molecule 193 trials (12 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	193	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 166 trials (36 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	166	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall molecule 163 trials (73 active) · roll-up of the cancer and its descendants	—	—	Malignant Digestive System Neoplasm	163	Observed	clinicaltrials	graph →

Malignant Digestive System Neoplasm studied in …STUDIED_INderived10 of 13,632show all (up to 200)
→ studied in	NCT00034216recruiting Collection of Blood From Patients With Cancer · condition mapped CURATED_EXACT · 13,632 trials mapped (4,101 active)	—	—	Malignant Colon Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00068003enrolling by invitation Harvesting Cells for Experimental Cancer Treatments · condition mapped ALIAS · 13,632 trials mapped (4,101 active)	—	—	Malignant Digestive System Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02595957recruiting Genomic Services Research Program · condition mapped CURATED_EXACT · 13,632 trials mapped (4,101 active)	—	—	Malignant Colon Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03030404completed Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer · condition mapped CURATED_EXACT · 13,632 trials mapped (4,101 active)	—	—	Malignant Gastric Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03623464NA · suspended RCT of Mobile Apps & FitBit v. Usual Care · condition mapped CURATED_EXACT · 13,632 trials mapped (4,101 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04415853Phase 3 · recruiting Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer · condition mapped CURATED_EXACT · 13,632 trials mapped (4,101 active)	—	—	Malignant Esophageal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04645160Phase 1/Phase 2 · recruiting Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers · condition mapped ONTOLOGY_EXACT · 13,632 trials mapped (4,101 active)	—	—	Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04868149NA · completed Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS · condition mapped CURATED_EXACT · 13,632 trials mapped (4,101 active)	—	—	Malignant Liver Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ONTOLOGY_EXACT · 13,632 trials mapped (4,101 active)	—	—	Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05048368Phase 1 · withdrawn Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function · condition mapped CURATED_EXACT · 13,632 trials mapped (4,101 active)	—	—	Malignant Esophageal Neoplasm	1	Observed	clinicaltrials	graph →